Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
EU Funding & Tenders Portal HORIZON-HLTH-2027-02-TOOL-01-two-stage · Horizon Europe (HORIZON)
| Funder | European Commission |
|---|---|
| Status | open |
| Opens | 29 Oct 2026 |
| Deadline | 17 Feb 2027 — 110 days |
| Action | HORIZON Research and Innovation Actions |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Last checked | 2026-10-30 06:02:40+00:00 |
The scope text was read and no clause in it rules a field out. That is not a guarantee — read the call before you commit to it.
You are reading one call. 1,058 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
This call page is free · no account · the report arrives by emailWhat this call is
| Instrument | HORIZON-RIA |
|---|---|
| Stages | two-stage |
| EU contribution | €6.0m to €8.0m per project |
| Projects expected | 6, sharing €44.2m |
From the Commission's own budget table for this call. Confirm against the topic page before you plan around it: these move when a work programme is amended.
Scope
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Clinical researchers and developers have access to novel predictive biomarkers to guide a more accurate assessment of disease progression and treatment response and tackle the unmet clinical needs of non-communicable chronic diseases. Clinicians and healthcare professionals use clinically validated predictive biomarkers for implementing more effective clinical research and personalised medicine with better health outcomes in chronic non-communicable diseases. Key stakeholders have access to trustworthy Artificial Intelligence (AI) tools to guide the development of multimodal predictive biomarkers of higher accuracy and clinical value when compared to the established practice. The citizens benefit of better health outcomes thanks to improved clinical guidelines and the implementation of effective biomarker-guided clinical research and personalised healthcare. Scope: Biomarkers [1] are invaluable tools for improving patient outcomes, guiding treatment decisions, accelerating personalised medicine, more effective clinical research and the development of better medicines. However, despite the scientific discoveries of many clinically relevant biomarkers, estimated on the scale of tens of thousands, only a few biomarkers have been implemented in clinical practice. The traditional ‘one biomarker’ paradigm is insufficient for addressing the unmet clinical needs of chronic, progressive and multifactorial diseases, due to the complexity of the clinical phenotypes characterised by broad inter-and intra-patient heterogeneity. The established biomarkers have limitations in their use as prognostic and predictive indicators, for the assessment of the disease progression and the choices of the optimal therapeutic interventions tailored to the patients’ characteristics. Therefore, the topic focuses on the clinical development of predictive biomarkers of disease progression and treatment response for chronic non-communicable diseases (excluding cancer) by using established AI methodologies able to combine data of clinically used and candidate biomarkers, with available data from relevant clinical studies, longitudinal and Real-World Data (RWD) [2] . This topic is expected to su…
Get told when something changes
Most institutions find out about a call with three weeks left. We write when something opens, moves or closes that fits what you work on, with the deadline, the fit and the funder's own exclusion clauses quoted. Nothing in a quiet week. Free, and one click to leave.
Starting from the programme you are reading: Horizon Europe (HORIZON) — change it below if you like.
Leave the second box empty and you get whatever opened or changed recently, closing soonest. Fill it in and it ranks against your words instead: that is the difference between a list and a shortlist.
Scientific Network Management will send you the current list for these terms, and after that only what changes: a call that opens, a deadline that shifts, a clause that rules you out. Nothing is sent when nothing has moved. One click to stop, in every message.
One confirmation email and nothing else until you click it. No tracking pixels, no sharing, one click to unsubscribe.
Of every 100 Horizon Europe proposals
A funding strategy reads your institution's own published record against the calls that are open, and says in writing which are worth the year and which to decline, with the reason for each.
Scientific Network Management, the grant-writing practice behind this radar: 13 years of EU-funded research projects, and a founder who has served as Key Expert and Team Leader on two EU-funded technical assistance contracts establishing biotechnology centres in Türkiye.
SNM also does
No obligation, and nothing here is conditional on using us: searching the calls stays free and asks for nothing either way.